Table 2.
Open and Recently Completed Clinical Trials for Pediatric Cancers Employing Adoptive NK cell therapy
| Clinical Trial Number | Title | Sponsor |
|---|---|---|
| NCT00582816 | Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors | University of Wisconsin, Madison |
| NCT00640796 | Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors | St. Jude Children's Research Hospital |
| NCT01287104 | A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias | National Cancer Institute |
| NCT01386619 | NK DLI in Patients After HLA-haploidentical HSCT | University Hospital, Basel, Switzerland |
| NCT01700946 | Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | St. Jude Children's Research Hospital |
| NCT01875601 | NK White Blood Cells and Interleukin in Children and Young Adults with Advanced Solid Tumors | National Cancer Institute |
| NCT01795378 | Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation (DNKI-II) | Asan Medical Center |
| NCT00896701 | Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2 | Cancer and Leukemia Group B |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium |
| NCT01823198 | Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies | M.D. Anderson Cancer Center |
| NCT00877110 | Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | Memorial Sloan-Kettering Cancer Center |
| NCT00526292 | Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant | Memorial Sloan-Kettering Cancer Center |
| NCT01621477 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | St. Jude Children's Research Hospital |
| NCT01576692 | A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents With Recurrent/Refractory Neuroblastoma (GD2NK) | St. Jude Children's Research Hospital |
| NCT00145626 | HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies | St. Jude Children's Research Hospital |
| NCT01857934 | Therapy for Children With Advanced Stage Neuroblastoma | St. Jude Children's Research Hospital |
| NCT00995137 | Genetically Modified Haploidentical Natural Killer Cell Infusions for B- Lineage Acute Lymphoblastic Leukemia | St. Jude Children's Research Hospital |
| NCT00703820 | Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia | St. Jude Children's Research Hospital |
| NCT01807611 | KIR Mismatched Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy | St. Jude Children's Research Hospital |